OncoDxRx Showcases Advanced Applications of One-Of-A-Kind PGA Test in Taiwan

OncoDxRx, a transformative liquid biopsy (LBx) company, is set to demonstrate its cutting-edge plasma mRNA-based treatment-supporting assay in Taiwan. This presentation underscores OncoDxRx’s commitment to providing innovative solutions for scenarios where cancer patients become unresponsive to targeted therapy, immunotherapy or chemotherapy. 

The PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) platform, is a testament to the LBx-transforming efforts of OncoDxRx. OncoDxRx specializes in the development and commercialization of exclusive and disruptive LBx technologies, possessing unique expertise in cell-free mRNA (cfmRNA) technology. 

PGA innovation allows non-responders (of targeted therapy) to match a number of anticancer drugs via a cfmRNA expression signature from the patient’s own blood. Coupling with in silico analyses further enhance the technology’s predictive power without compromising its turnaround and cost. 

The PGA assay is seamlessly adaptable to various RT-qPCR platforms which have been used extensively in COVID-19 screening. Notably, all instruments are already in active service with most of the clinical laboratories around the world.

In addition to PGA, OncoDxRx will present a range of LBx solutions designed to address the unmet patient and market needs in precision oncology.